Briefing
Using Circulating Tumor DNA-Based Molecular Residual Disease Detection for Postoperative Monitoring in Early-Stage Uterine Cancer
JCO Precision Oncology report on ctDNA-based MRD for postoperative monitoring in early-stage uterine cancer, overlapping investigators with the Recio 2024 Signatera stage I series.
- Design: Evidence level 3
- Assay: Not named in the abstract